Company news

Mesoblast Limited news in 2020

Mesoblast Limited's news releases, calls and decks from 2020, newest first.

View company

Mesoblast Update on COVID-19 ARDS Trial

December 17, 2020

Trading halt

December 16, 2020

Mesoblast Phase 3 Chronic Heart Failure Results

December 14, 2020

Remestemcel-L FDA Fast Track Designation for COVID-19 ARDS

December 1, 2020

Novartis and Mesoblast Remestemcel-L Collaboration

November 19, 2020

First Quarter Results Presentation

November 19, 2020

DSMB Analysis Recommends to Continue P3 COVID-19 ARDS Trial

November 10, 2020

COVID-19 ARDS & GVHD Update, Quarterly Report & Appendix 4C

October 28, 2020

MSB Wins Fierce Biotech Innovation Award for Remestemcel-L

September 15, 2020

DSMB Recommends Continuation of Phase 3 COVID-19 Trial

September 4, 2020

ODAC Votes in Favor of Remestemcel-L for GvHD

August 14, 2020

Update on Scheduled FDA Advisory Committee Meeting

August 11, 2020

COVID-19/GVHD Update, Quarterly Report and Appendix 4C

July 30, 2020

FDA Advisory Committee Sets Review Date for Remestemcel-L

July 20, 2020

S&P DJI Announces June 2020 Quarterly Rebalance

June 11, 2020

Remestemcel-L Improves Outcomes in Inflammatory Lung Disease

June 1, 2020

MSB Completes Financing For Covid-19 ARDS Manufacturing

May 13, 2020

Phase 2/3 Trial in COVID-19 ARDS Begins Enrollment

April 29, 2020

83% Survival in COVID-19 ARDS Patients with Remestemcel-L

April 24, 2020

US NIH Trials Network to Conduct COVID-19 Phase 2/3 Trial

April 8, 2020

FDA Clears IND for Remestemcel Use in COVID-19 ARDS Patients

April 5, 2020

FDA Accepts BLA for RYONCIL and Agrees to Priority Review

March 31, 2020

Mesoblast to Evaluate Remestemcel-L in COVID-19 Lung Disease

March 9, 2020

Mesoblast Provides Half Year Results and Corporate Update

February 26, 2020

Mesoblast Submits Completed BLA for Ryoncil to US FDA

February 2, 2020

Appendix 4C - quarterly

January 28, 2020

MSB Files GvHD Clinical Efficacy and Safety Data with US FDA

January 1, 2020

Decks in 2020